Targeting the Delivery of Glycan-Based Paclitaxel Prodrugs to Cancer Cells via Glucose Transporters
- 16 November 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (23), 7428-7441
- https://doi.org/10.1021/jm8006257
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activationProceedings of the National Academy of Sciences of the United States of America, 2007
- Synthesis of 2′-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cellsBioorganic & Medicinal Chemistry Letters, 2007
- Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agentsJournal of Drug Targeting, 2007
- Hypoxia in head and neck cancerThe British Journal of Radiology, 2006
- Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxiaThe FASEB Journal, 2005
- Recent advances in tumor-targeting anticancer drug conjugatesBioorganic & Medicinal Chemistry, 2005
- Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell CarcinomaMolecular and Cellular Biology, 2005
- Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancerJournal of Cellular Physiology, 2004
- Active Site Residues of Human β-GlucuronidaseOnline Journal of Public Health Informatics, 1999
- Studies toward structure-activity relationships of taxol®: synthesis and cytotoxicity of taxol® analogues with C-2′ modified phenylisoserine side chainsBioorganic & Medicinal Chemistry Letters, 1993